Opioid Overdose
46
6
9
22
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
2.2%
1 terminated out of 46 trials
95.7%
+9.1% vs benchmark
15%
7 trials in Phase 3/4
45%
10 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (46)
Pharmacokinetic (PK) Evaluation of Nalmefene Formulations
Vending Machine Naloxone Distribution for Your Community (VENDY)
Clinical Decision Support to Improve System Naloxone Co-prescribing
UnityPhilly Response App for Overdose Reversal
Evaluation of Clinical Decision Support in Opioid Tapering
A Bundled Intervention to End Opioid Overdoses
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
Preventing Overdose Using Information and Data From the Environment
Tailoring Overdose Education for Black Churches
Quantitative Xylazine Measurement in ED
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
A Bundled Intervention
Opioid Rapid Response System: Naloxone Training in Communities
A Model to Save Lives Through a Volunteer First Responder Service Providing Antidote Treatment in Opioid Overdose
Young Houston Emergency Opioid Engagement System
The Rhode Island Prescription and Illicit Drug Study
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal
Naloxone for Opioid Associated Out of Hospital Cardiac Arrest
Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose